Aethlon Medical, Inc. — Form 10-Q Summary
Reporting period: Third quarter of fiscal 2024, three and nine months ended December 31, 2023. Filed February 14, 2024. The company is a clinical-stage medical device developer; its Hemopurifier targets cancer-related exosomes and certain viruses. The filing reports no revenue for the periods presented.
Key financial metrics
| Metric | Three months ended Dec. 31, 2023 | Nine months ended Dec. 31, 2023 | Comparable 2022 period |
|---|---|---|---|
| Operating expenses | $3.57 million | $10.15 million | $2.85 million; $9.42 million |
| Operating loss | $3.57 million | $10.15 million | $2.85 million; $9.42 million |
| Net loss | $3.47 million | $9.78 million | $2.85 million; $9.56 million |
| Loss per share, basic and diluted | $1.37 | $3.95 | $1.24; $4.84 |
| Net cash used in operations | Not provided for quarter | $7.56 million | $7.56 million for nine months |
Quarterly net loss was partly offset by $101,000 of interest and other income; operating loss was $3.57 million. Gross and operating margins are not meaningful because the filing reports no revenue.
- Liquidity at December 31, 2023: Cash of $7.97 million, restricted cash of $87,506, working capital of $6.15 million, and current liabilities of $2.10 million. Cash was $14.53 million and working capital $13.59 million at March 31, 2023.
- Cash flows, nine months: Investing activities used $246,000; financing activities provided $1.25 million, mainly from ATM share sales. Cash and restricted cash declined $6.56 million to $8.06 million.
- Debt and leases: The balance sheet lists no borrowings. Lease liabilities totaled about $1.01 million, including $285,000 current and $725,000 long-term.
- Equity financing: The company raised $1.27 million net through its ATM program during the nine months, selling 272,195 shares at an average $4.68 per share. After quarter-end, it raised another $49,762 net. Shares outstanding were 2,596,538 at December 31 and 2,620,399 at February 9, 2024.
Material changes versus prior periods
- Nine-month operating expenses rose 7.7% year over year, driven chiefly by higher payroll and professional fees. Lower clinical-trial, subcontracting, and rent costs partly offset the increases.
- Nine-month net loss increased to $9.78 million from $9.56 million. Loss per share improved to $3.95 from $4.84, reflecting a higher weighted-average share count.
- Third-quarter operating expenses rose 25.2% to $3.57 million, primarily due to former CEO separation-related costs and higher payroll; lower clinical-trial and other expenses partly offset the increase.
- Cash used in operations was broadly unchanged year over year. ATM proceeds fell to $1.27 million from $8.93 million in the prior-year nine-month period, contributing to the decline in cash.
- A 1-for-10 reverse stock split took effect October 4, 2023; share and per-share figures were retroactively adjusted in the filing.
Outlook, developments, and risks
- Going concern: Management says existing cash is not sufficient to fund operations for at least 12 months from issuance of the financial statements. The filing states that substantial doubt exists about the company’s ability to continue as a going concern. It expects to seek debt or equity financing and potentially collaborations or strategic partnerships; success and availability of funding are not assured.
- Clinical and regulatory plans: The company is preparing an Australia oncology trial and has Indian regulatory clearance for a Phase 1 solid-tumor trial, which remains contingent on an internal binding study and ethics approvals. It is also pursuing COVID-19 studies in India and exploratory organ-transplant research. Its U.S. COVID-19 feasibility study was terminated in 2022 because of insufficient eligible patients at trial sites.
- Manufacturing: The first manufacturing lot using the current GNA supplier was approved and released in late December 2023. The transition to a second GNA supplier remains delayed pending FDA action on an IDE supplement. Management reports sufficient devices for planned Australia and India oncology trials.
- Unusual items and leadership: Former CEO Charles Fisher’s separation agreement included 12 months of $460,000 aggregate cash severance, continued medical coverage, and accelerated vesting of half of his unvested options. The company recorded $891,844 of total separation-related expense for the quarter. James Frakes became interim CEO while retaining the CFO role; Guy Cipriani was appointed COO.
- Principal risks: Continued losses and financing dependence, potential dilution, clinical and regulatory uncertainty, supplier qualification and manufacturing delays, Nasdaq listing compliance, and dependence on key executives. The filing identifies no pending or threatened legal proceedings. Management reported disclosure controls were effective and no material quarterly change in internal control over financial reporting.
- Guidance: No specific revenue, earnings, or cash-flow guidance is provided. Management expects negative cash flows and net losses to continue and clinical-trial costs to increase as programs advance.
Important facts for investors to verify
- Cash runway, near-term cash requirements, and progress securing financing; assess potential dilution and the going-concern warning.
- FDA status and timing for qualifying the second GNA supplier, and manufacturing readiness for planned U.S. trials.
- Actual start dates, site approvals, enrollment plans, and funding needs for the Australia and India oncology trials.
- Reconciliation of the $891,844 quarter separation expense with the filing’s separately described severance and payroll amounts.
- Nasdaq listing compliance and subsequent share issuance under the ATM program.